Oropharyngeal Cancer Clinical Trial
Official title:
Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135]
This phase I/II trial is studying the side effects and best dose of gene therapy and to see how well it works in preventing cancer in patients with premalignant carcinoma of the oral cavity or pharynx. Inserting the p53 gene into a person's tumor cells may improve the body's ability to kill the tumor cells
Status | Completed |
Enrollment | 51 |
Est. completion date | |
Est. primary completion date | August 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed mild to moderate dysplasia OR severe dysplasia/carcinoma in situ of the oral cavity or oral pharynx - Clinically evident diffuse premalignant disease, defined by 1 of the following mucosal abnormalities: - Extension between adjacent organ structures (e.g., lateral tongue, ventral tongue, and the floor of the mouth) - Extensive surface area, including the entire ventral tongue or floor of the mouth or buccal mucosa, in a velvety "indiscreet" pattern - Meets 1 of the following criteria: - Previously treated with conventional treatment (e.g., radiotherapy or surgery) for a prior head and neck malignancy - Failed biochemoprevention approaches for premalignant disease - Failed other therapeutic approaches for premalignant disease - No active squamous cell carcinoma of the head and neck - Performance status - Karnofsky 70-100% - Absolute granulocyte count at least 2,000/mm^3 - Platelet count at least 100,000/mm^3 - Bilirubin no greater than 1.0 mg/dL - Creatinine no greater than 1.5 mg/dL - No hypertension (baseline blood pressure 140/90 mm Hg or higher) - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier contraception during and for 1 year after study participation - HIV-1 negative - No known contact with former tissue or organ transplantation recipients or individuals with severe immunodeficiency disease (acquired or congenital) during and for 28 days after study treatment - No prior malignancy within the past 2 years except nonmelanoma skin cancer or aerodigestive cancer - No active systemic viral, bacterial, or fungal infections requiring treatment - No serious concurrent illness that would preclude study compliance and follow-up - No psychological, familial, sociological, geographical, or other condition that would preclude study compliance and follow-up - See Disease Characteristics - More than 21 days since prior chemotherapy (42 days for mitomycin and nitrosoureas) - No concurrent systemic chemotherapy - No concurrent prednisone or the equivalent, including corticosteroids of more than 10 mg/day - See Disease Characteristics - More than 3 months since prior radiotherapy involving the lesion selected for this study - No concurrent radiotherapy - See Disease Characteristics - More than 8 weeks since prior investigational agents - No prior experimental therapy (i.e., oral, systemic, topical, or direct injection) for the lesion selected for treatment in this study - No other concurrent immunosuppressive therapy - No other concurrent investigational agents - No concurrent aspirin dose greater than 175 mg/day |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | M D Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of adverse events | Up to 15 years | Yes | |
Primary | Severity of adverse events graded using the CTCAE version 3.0 | Up to 15 years | Yes | |
Primary | Maximum tolerated dose of Ad5CMV-p53 gene | Evaluated by the frequency and relationship of dose-limiting toxicities, if any, experienced by patients during dose escalation. | 6 months | Yes |
Primary | Pharmacodynamics evaluated by examining the injected precancerous lesion for induction of apoptosis and expression of the p53 protein | Presented using descriptive statistics, frequency tabulations, and graphical displays over time by treatment cohort. | 168 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03656133 -
Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers
|
N/A | |
Terminated |
NCT02225496 -
Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
|
Phase 2 | |
Withdrawn |
NCT01767961 -
Modified Barium Swallow in Measuring Swallowing Function After Surgery in Patients With Oropharyngeal Cancer
|
N/A | |
Completed |
NCT01695122 -
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01435252 -
A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab
|
Phase 2 | |
Recruiting |
NCT04708470 -
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00951470 -
Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema
|
N/A | |
Completed |
NCT01358097 -
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
|
N/A | |
Completed |
NCT00964977 -
Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.
|
Phase 3 | |
Completed |
NCT01342978 -
Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time
|
N/A | |
Recruiting |
NCT05363709 -
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
|
Phase 2 | |
Completed |
NCT02280811 -
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
|
Phase 2 | |
Active, not recruiting |
NCT03777384 -
EValuating the Safety Of De-escaLated Head and Neck Irradiation in HPV positivE Oropharynx Cancer in Non-smokers/Minimal Smokers
|
||
Active, not recruiting |
NCT03729518 -
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
|
N/A | |
Recruiting |
NCT06121102 -
Standard Pulsed Radiofrequency Versus Supervoltage Pulsed Radiofrequency Glossopharyngeal Nerve in Oropharyngeal Cancer Pain
|
N/A | |
Recruiting |
NCT02984410 -
Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma
|
N/A | |
Recruiting |
NCT02960724 -
uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer
|
Phase 2 | |
Completed |
NCT02934724 -
Impact of HPV Vaccine On The Prevalence Of HPV In Norway
|
||
Withdrawn |
NCT00928161 -
Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy
|
N/A | |
Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|